^
    BIOMARKER:

    HER-2 overexpression

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    HER-2 overexpression
    Gastric Cancer
    trastuzumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    HER2 Positive Breast Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    HER2 Positive Breast Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    HER2 Positive Breast Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    HER2 Positive Breast Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    HER2 Positive Breast Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    lapatinib
    Sensitive: A1 - Approval
    HER-2 overexpression
    Hormone Receptor Negative Breast Cancer
    trastuzumab + lapatinib
    Sensitive: A1 - Approval
    HER-2 overexpression
    Breast Cancer
    lapatinib
    Sensitive: A1 - Approval
    HER-2 overexpression
    Breast Cancer
    trastuzumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Breast Cancer
    trastuzumab / hyaluronidase-oysk
    Sensitive: A1 - Approval
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    neratinib
    Sensitive: A1 - Approval
    HER-2 overexpression
    Breast Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Breast Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Breast Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Breast Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Breast Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    HER2 Positive Breast Cancer
    trastuzumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Breast Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Breast Cancer
    trastuzumab + docetaxel
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    HER2 Positive Breast Cancer
    neratinib
    Sensitive: A1 - Approval
    HER-2 overexpression
    Esophageal Adenocarcinoma
    trastuzumab
    Sensitive: A2 - Guideline
    HER-2 overexpression
    Gastric Adenocarcinoma
    trastuzumab
    Sensitive: A2 - Guideline
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A2 - Guideline
    HER-2 overexpression
    Esophageal Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A2 - Guideline
    HER-2 overexpression
    Gastric Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A2 - Guideline
    HER-2 overexpression
    Gastric Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A2 - Guideline
    HER-2 overexpression
    Gastric Adenocarcinoma
    pembrolizumab + trastuzumab
    Sensitive: A2 - Guideline
    HER-2 overexpression
    Esophageal Cancer
    pembrolizumab + trastuzumab
    Sensitive: A2 - Guideline
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab + trastuzumab
    Sensitive: A2 - Guideline
    HER-2 overexpression
    Gastric Cancer
    lapatinib
    Sensitive: B - Late Trials
    HER-2 overexpression
    Breast Cancer
    neratinib
    Sensitive: B - Late Trials
    HER-2 overexpression
    HER2 Positive Breast Cancer
    trastuzumab + lapatinib
    Sensitive: B - Late Trials
    HER-2 overexpression
    HER2 Positive Breast Cancer
    lapatinib
    Sensitive: B - Late Trials
    HER-2 overexpression
    Solid Tumor
    CT-0508
    Sensitive: B - Late Trials
    HER-2 overexpression
    Gallbladder Cancer
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 overexpression
    Endometrial Adenocarcinoma
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 overexpression
    Endometrial Cancer
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 overexpression
    Esophageal Cancer
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 overexpression
    Pancreatic Cancer
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 overexpression
    Salivary Gland Cancer
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 overexpression
    Cervical Cancer
    trastuzumab
    Resistant: C1 - Off-label
    HER-2 overexpression
    Urothelial Cancer
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 overexpression
    Cholangiocarcinoma
    lapatinib
    Sensitive: C1 - Off-label
    HER-2 overexpression
    Gastric Cancer
    ASLAN001
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    Salivary Gland Cancer
    trastuzumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    HER2 Positive Breast Cancer
    trastuzumab + pertuzumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    Gastric Cancer
    disitamab vedotin
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    Breast Cancer
    trastuzumab + pertuzumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    HER2 Positive Breast Cancer
    HM 78136B
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    Ovarian Cancer
    trastuzumab + pertuzumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    CRC
    trastuzumab + pertuzumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    Gastric Cancer
    pembrolizumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    NSCLC
    fam-trastuzumab deruxtecan-nxki
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Her-VAXX
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    Urothelial Cancer
    disitamab vedotin
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    Breast Cancer
    eribulin mesylate
    Sensitive: C2 – Inclusion Criteria
    HER-2 overexpression
    Biliary Tract Cancer
    ZW25
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    CRC
    cetuximab
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Solid Tumor
    KN046 + KN026
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Gastroesophageal Cancer
    disitamab vedotin
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Gastric Cancer
    cabazitaxel
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Esophageal Adenocarcinoma
    trastuzumab + pertuzumab
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Endometrial Cancer
    trastuzumab + pertuzumab
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    HER2 Positive Breast Cancer
    ado-trastuzumab emtansine
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Gastric Cancer
    ado-trastuzumab emtansine
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    NSCLC
    trastuzumab + pertuzumab
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Pancreatic Cancer
    trastuzumab + pertuzumab
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Bladder Cancer
    trastuzumab + pertuzumab
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Salivary Gland Cancer
    trastuzumab + pertuzumab
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    HER2 Positive Breast Cancer
    ZW25
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Gastroesophageal Cancer
    ZW25
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Gastric Cancer
    AT101
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    CRC
    EGFR inhibitor
    Resistant: C3 – Early Trials
    HER-2 overexpression
    Breast Cancer
    simvastatin
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Uterine Cancer
    trastuzumab + pertuzumab
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    HER2 Positive Breast Cancer
    ado-trastuzumab emtansine
    Sensitive: C3 – Early Trials